ImmunoPrecise Antibodies Secures Extended Compliance Timeline Following Nasdaq Capital Market Relocation

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a biotherapeutic innovator focused on artificial intelligence-driven antibody therapeutics, has received clearance from Nasdaq Listing Qualifications to transition its listing venue. The relocation from Nasdaq Global Market to Nasdaq Capital Market takes effect at market open on February 21, 2025, a strategic move that grants the company a fresh 180-day compliance window through August 18, 2025, to satisfy the minimum share price requirement of $1.00.

This transition underscores IPA’s commitment to maintaining its public market presence while advancing its corporate development agenda. The extended compliance period provides the company with additional runway to stabilize its stock valuation and execute operational milestones without facing immediate delisting pressures.

The Relocation Framework

The shift to Nasdaq Capital Market aligns with standard Nasdaq regulatory procedures and preserves IPA’s public equity status. Rather than facing potential removal, the company now operates under the Capital Market’s listing requirements, which accommodate companies in growth or transition phases. This regulatory accommodation reflects Nasdaq’s approach to supporting companies navigating market volatility while they pursue strategic initiatives.

Company Profile and Market Position

ImmunoPrecise Antibodies operates through a diversified subsidiary structure—encompassing Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V.—to deliver comprehensive antibody development solutions. The organization leverages systems biology, multi-omics data integration, and machine learning platforms to engineer fully human therapeutic antibodies targeting complex disease indications.

By consolidating discovery, development, and commercialization capabilities across geographies, IPA positions itself as an end-to-end partner for next-generation antibody therapeutics. This vertically integrated model distinguishes the company within the competitive biologics landscape.

What’s Next

With the 180-day compliance clock now running, IPA faces a clear timeline to achieve sustained pricing above the $1.00 threshold. Stakeholders will be monitoring the company’s progress on clinical programs, partnership announcements, and financial metrics as these factors typically influence equity performance during compliance periods.